Appointment of finnCap Ltd. as Corporate Broker

RNS Number : 9120A

Oxford Cannabinoid Tech.Holdings

28 September 2022

 

28 September 2022

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or "the Company")

Appointment of finnCap Ltd as Corporate Broker

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market, is pleased to announce the appointment of finnCap Ltd ("finnCap") as corporate broker to the Company with immediate effect (www.finncap.com).

finnCap will work alongside the Company's existing corporate broker, Axis Capital Markets and financial adviser, Cairn Financial Advisers LLP.

Dr John Lucas, OCTP CEO said: "The addition of finnCap as corporate broker, with their specific life sciences expertise, is a real advantage for the Company. We are delighted that finnCap are on board and know they will complement the support that our existing advisers have provided."

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc Dr John Lucas (CEO) Clarissa Sowemimo-Coker (COO)	[phone] [e-mail] [e-mail]
Cairn Financial Advisers LLP Emily Staples Jo Turner	[phone] [phone]
Axis Capital Markets Limited Kamran Hussain Richard Hutchison finnCap Ltd James Thompson/Geoff Nash/Fergus Sullivan Nigel Birks (ECM) Walbrook PR Limited Paul Vann/Nick Rome Harbor Access LLC Richard Leighton/Jonathan Paterson	[phone] [phone] [phone] [phone] [e-mail] [phone] [e-mail]

About Oxford Cannabinoid Technologies Holdings plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the "Group"). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with clinical trials scheduled for Q1 2023. The Group's product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial partners.

 

END

 

 

APPKDLFLLKLLBBV